Lysosomal Nutrient Sensing and Metabolic Signaling
Lysosomes function not only as degradative organelles but also as central hubs that integrate
nutrient availability with global metabolic signaling. They receive inputs from both
extracellular and intracellular sources, including endocytosed macromolecules and autophagic
cargoes, which are degraded into amino acids, lipids, sugars, and other catabolites within the
acidic lysosomal lumen. These degradation products are exported into the cytoplasm, where they
serve as metabolic cues sensed at the lysosomal surface.
The lysosomal membrane contains an integrated nutrient-sensing machinery composed of protein
complexes, transporters, and ion pumps. These components detect fluctuations in metabolite
availability and transmit signals to downstream signaling pathways. The resulting signaling
outputs coordinate anabolic and catabolic processes, modulate cellular energy homeostasis, and
enable dynamic adaptation to nutrient stress.
Figure 1. The lysosome is a nutrient sensing, processing and signaling center[1].
In this section, we discuss two key mechanisms by which lysosomes transduce nutrient signals
into coordinated cellular responses: (1) the mTORC1-Rag GTPase axis, (2) V-ATPase and pH
sensing.
mTORC1-Rag GTPase axis
One of the best-characterized mechanisms linking lysosomal nutrient sensing to metabolic
signaling is activation of mechanistic target of
rapamycin complex 1
(mTORC1) through the Rag GTPase axis. Rag GTPases are membrane-anchored heterodimers
composed of RagA or RagB bound to RagC or RagD. Their nucleotide-loading states function as
molecular switches that reflect intracellular nutrient availability.
Under nutrient-rich conditions, particularly in the presence of abundant amino acids, RagA/B are
loaded with GTP while RagC/D are loaded with GDP, forming the active heterodimer. This active
complex interacts directly with the mTORC1 component Raptor to recruit mTORC1 to the lysosomal
surface. Once localized to lysosomes, mTORC1 is activated by Rheb and subsequently promotes
downstream anabolic signaling pathways involved in protein synthesis, lipid biosynthesis, and
cell growth.
In contrast, nutrient deprivation promotes GTP hydrolysis on RagA/B and GDP loading on RagC/D,
generating the inactive Rag configuration. This prevents recruitment of mTORC1, suppresses
anabolic signaling, and activates catabolic pathways such as autophagy.
Figure 2. A nutrient-sensitive catch-and-release mechanism regulates mTORC1 localization to the
lysosome[2].
V-ATPase and pH sensing
Vacuolar-type H+ -ATPase (V-ATPase) is a multisubunit proton pump responsible for establishing
and maintaining the highly acidic lumenal pH characteristic of late endosomes and lysosomes. It
achieves this by actively translocating protons (H+) from the cytosol into the lysosomal lumen.
Lysosomal pH gradients established by V-ATPase serve as indirect sensors of cellular metabolic
status, as alterations in lumenal acidification influence the activity and conformational
dynamics of nutrient sensors and transporters embedded within the membrane.
Importantly, V-ATPase assembly and activity are themselves dynamically regulated by cellular
energy and nutrient states. Under conditions such as glucose limitation or amino acid
starvation, V
1 and V
0 domains can dissociate, leading to reduced proton pumping activity and
partial lysosomal deacidification. These changes feeds back into metabolic signaling pathways,
coordinating catabolic activation (e.g.,
autophagy) while
suppressing anabolic processes during nutrient scarcity.
Figure 3. v-ATPase structure and regulation by dissociation[3].
Lysosomal Quality Control and Cellular Adaptation
Lysosomes are essential not only for nutrient sensing and metabolic signaling, but also for
maintaining cellular integrity through a network of quality control mechanisms. As the
principal degradative compartment in eukaryotic cells, lysosomes coordinate multiple
pathways that ensure efficient breakdown and recycling of intracellular material, thereby
preventing the accumulation of damaged proteins and dysfunctional organelles.
Under conditions of stress or cellular damage, lysosomal quality control mechanisms activate
degradation pathways, identify and eliminate impaired organelles, and redistribute metabolic
resources to support survival and adaptation.
In this section, we first outline the major lysosomal degradation pathways that maintain
cellular homeostasis, followed by discussing mechanisms responsible for organelle
surveillance and clearance.
Degradation Pathways and Cargo Turnover
The lysosome functions as the central degradative hub for diverse intracellular and
extracellular cargoes, ensuring the efficient turnover of biological macromolecules. As
illustrated in Figure 4, extracellular substrates enter the degradative network through
endocytosis or phagocytosis and subsequently mature through early and late endosomal stages
into endolysosomes or phagolysosomes. This pathway enables the cell to internalize
nutrients, receptor-ligand complexes, and pathogens for systematic processing and
elimination.
Simultaneously, lysosomes maintain intracellular homeostasis through autophagy.
Intracellular cargoes, such as damaged organelles or protein aggregates, are sequestered
within double-membrane autophagosomes, which subsequently fuse with the lysosome to form
autolysosomes. Additional degradative pathways, such as microautophagy and selective
membrane repair processes, further contribute to lysosomal homeostasis and proton balance.
Regardless of the origin, the terminal stage involves degradation and recycling, during
which macromolecules are broken down into reusable building blocks and exported back into
the cytoplasm. This continuous cargo turnover is essential for preventing accumulation of
cytotoxic debris and sustaining cellular bioenergetics.
Figure 4. Biogenesis of lysosomes[4].
Organelle Damage Surveillance and Removal
Cells maintain organelle integrity through dynamic quality control systems that detect,
isolate, and eliminate damaged or dysfunctional organelles. These mechanisms prevent
accumulation of toxic byproducts while preserving metabolic efficiency. A central component
for this surveillance is selective autophagy of organelles, collectively referred to as
organellophagy, in which specific organelles are targeted for lysosomal degradation.
Mitophagy selectively removes dysfunctional mitochondria through regulators such as PINK1
and Parkin, which accumulate on depolarized mitochondria and facilitate their encapsulation
within autophagosomes prior to lysosomal degradation. This process eliminates mitochondria
that generate excessive reactive oxygen species, thereby preserving cellular energy
homeostasis and limiting apoptotic signaling.
Similarly, the endoplasmic reticulum undergoes ER-phagy, where fragments of ER are
selectively delivered to lysosomes through macroautophagic or microautophagic pathways to
maintain ER function and prevent proteotoxic stress. Comparable mechanisms also exist for
peroxisomes (pexophagy), lipid droplets (lipophagy) and additional organelles, each
employing specialized receptors or adaptors to recognize damaged subdomains and recruit
autophagic machinery.
Figure 5. A scheme illustrating all currently known modes of clearance of plant organelles
or their components by selective-autophagy[5].
Lysosome-Associated Diseases and Emerging Therapeutic Opportunities
Lysosomal dysfunction contributes to the pathogenesis of a wide spectrum of human diseases,
including neurodegenerative disorders, cancer, and metabolic diseases. In many cases,
lysosomal impairment precedes overt clinical pathology and represents an early indicator of
neuronal dysfunction.
In neurodegenerative diseases, impaired lysosomal degradation contributes to progressive
accumulation of toxic proteins and damaged organelles. In cancer, altered lysosomal
signaling and trafficking reprogram metabolic and growth pathways that support tumor
progression and therapeutic resistance.
These insights have accelerated development of lysosome-targeted therapeutic strategies.
Beyond conventional enzyme replacement therapies and small-molecule modulators, emerging
approaches increasingly exploit the lysosomal degradative machinery itself to selectively
eliminate disease-associated proteins.
Lysosomal Dysregulation and Neurodegeneration
In
neurodegeneration disorders, impaired lysosomal
acidification, defective autophagic flux, and disrupted proteolytic
clearance lead to the progressive accumulation of toxic protein aggregates and dysfunctional
organelles. These pathological
features are central to diseases such as
Alzheimer disease
(AD) and
Parkinson's disease (PD).
Under physiological conditions, acidified lysosomes efficiently fuse with autophagosomes to
form functional autolysosomes, thereby enabling degradation of cellular debris and toxic
protein aggregates while maintaining neuronal homeostasis. However, when lysosomal
acidification becomes compromised, lysosomal degradative capacity progressively declines.
Inefficient degradation leads to accumulation of undegraded intracellular cargo, triggering
a cascade of neurodegenerative pathologies.
During early disease stages, stressed neurons exhibit altered neuronal structures,
mitochondrial dysfunction, and elevated
inflammatory cytokine production, and formation of protein oligomers such as
Tau,
Aβ, and
α-synuclein. As disease progresses,
these oligomeric species evolve into insoluble aggregates such as Tau tangles, Aβ plaques,
and Lewy bodies, ultimately
resulting in neuronal loss, brain atrophy, and cognitive or motor dysfunction.
Consequently, restoration of lysosomal acidification and degradative capacity has emerged as
a critical therapeutic strategy for slowing progression of neurodegenerative disease.
Figure 6. Role of lysosomal acidification dysfunction in early neurodegenerative
pathology[6].
Emerging evidence indicates that lysosomes are intricately involved in multiple aspects of
cancer cell biology, with significant implications for tumor progression and therapeutic
response.
Compared with normal cells, tumor cells frequently exhibit increased lysosomal number,
enlarged lysosomal volume, elevated expression of lysosomal enzymes, and altered spatial
distribution. A hallmark of aggressive cancers is redistribution of lysosomes from the
perinuclear region toward the cell periphery. Whereas lysosomes in normal cells are
typically clustered near the cell center for routine degradation, cancer cells hijack
molecular motor systems such as the BORC-Arl8b-KIF5B complex to drive lysosomal trafficking
toward the plasma membrane.
This peripheral redistribution correlates strongly with the increased invasive potential,
enabling focal
secretion of lysosomal enzymes into the
extracellular matrix
(ECM). In parallel, alterations in the lysosomal
membrane composition enhance tumor cell survival. Peripheral lysosomes often exhibit
increased lysosomal membrane permeabilization (LMP), which cancer cells counteract through
modulation of membrane-stabilizing factors.
In addition, peripheral lysosomes promote exocytosis of
cathepsins and other proteases that degrade the ECM and facilitate
metastatic dissemination. This dependence on lysosomal activity enables cancer cells to
survive in nutrient-poor microenvironments while actively remodeling surrounding tissues to
support tumor invasion and metastasis.
Figure 7. Cancer-associated changes affecting lysosomal positioning[7].
Lysosome-Targeted Therapeutic Modalities
Recognition of the lysosome's powerful degradative capacity has driven development of a new
generation of therapeutic modalities. Unlike traditional inhibitors that merely suppress
protein function, these emerging technologies aim to eliminate the disease-associated
proteins by redirecting them to the lysosomal degradation pathways.
As depicted in Figure 8, several innovative platforms have been developed to achieve
selective cargo recognition and subsequent degradation.
One of the most promising breakthroughs is the
LYTAC
(Lysosome-Targeting Chimera) technology. LYTACs utilize bifunctional molecules that
simultaneously bind a cell-surface receptor (such as M6PR) and a target extracellular or
membrane-associated protein. This interaction promotes endocytosis and directs the target
protein toward lysosome-mediated degradation. Importantly, LYTACs enable degradation of
secreted and membrane proteins that are inaccessible to proteasome-based degradation
systems.
Complementary autophagy-centered strategies exploit the cell's endogenous bulk degradation
machinery. AUTACs (autophagy-targeting chimeras) employ bifunctional molecules with a
target-binding warhead linked to an autophagy-inducing tag, such as a guanine derivative.
These molecules promote polyubiquitination and recruitment of autophagic receptors, thereby
directing proteins of interest into autophagosomes for lysosomal degradation.
ATTECs (autophagosome-tethering compounds) function differently by simultaneously binding a
target protein and LC3 on autophagic membranes, effectively tethering the target to
developing autophagosomes for subsequent lysosomal hydrolysis.
AUTOTAC (AUTOphagy-Targeting Chimera) further expands this strategy by engaging both target
proteins and the autophagy receptor SQSTM1/p62, thereby activating macroautophagic
sequestration into lysosomes independently of ubiquitination while enhancing autophagic
flux.
Beyond these targeted protein degradation technologies, Lysosome-Enhancing Compounds (LYECs)
represent small molecules that upregulate lysosomal biogenesis and function, often through
modulation of TFEB and related transcriptional programs. LYECs have demonstrated the
capacity to enhance lysosomal degradative activity in neurodegenerative disease models,
promoting clearance of pathogenic aggregates and improving cellular homeostasis.
Figure 8. A schematic illustration of LYTAC, AUTAC, ATTEC, AUTOTAC and LYECs[8].
Summary
The transition of the lysosome from a passive degradative organelle to a central metabolic
command hub represents
a landmark shift in cellular biology. Its ability to integrate complex nutrient signals with
cellular quality
control is essential for maintaining homeostasis under diverse physiological stresses.
Disruption of this
delicate balance is increasingly recognized as a key driver of neurodegeneration and cancer.
Continued advances
in our understanding of lysosomal networks, together with the emergence of lysosome-targeted
technologies such
as LYTACs, are opening new opportunities for precision therapeutics through the selective
elimination of
disease-associated targets at the molecular level.
Recommended Products
| Product Name |
Cat. No. |
Application |
| Lyso Tracker Red |
HY-D1300 |
Red fluorescent lysosome probe. |
| Lyso Tracker Red (solution) |
HY-DY1040 |
Red fluorescent lysosome probe (1 mM stock solution). |
| Lyso Tracker Yellow HCK 123 |
HY-D1694 |
Yellow fluorescent probe selectively accumulates in cellular compartments with low
luminal pH. |
| DQ-BSA-RED |
HY-D2449 |
Red fluorescent lysosomal activity probe |
| Bafilomycin A1 |
HY-100558 |
Specific and reversible inhibitor of vacuolar V-ATPase, blocks
autophagosome-lysosome fusion and inhibits acidification. |
| MHY1485 |
HY-B0795 |
Potent mTOR activator, inhibits autophagy by suppression of fusion between
autophagosomes and lysosomes. |
| Omeprazole |
HY-B0113 |
Orally active H+, K+-ATPase inhibitor and proton pump inhibitor. |
| Tri-GalNAc-DBCO |
HY-148476 |
Synthetic ligand composed of three GalNAc units connected to DBCO, ligand for ASGPR.
|
| β-Amyloid (1-42), human |
HY-P1363A |
Brain-penetrant amyloid protein fragment, frequently used in research on Alzheimer's
disease and Down's syndrome |
Note: MCE can provide products for research use only. We do not sell to patients.
LinkedIn
Researchgate
Facebook
X
Instagram
Mail
Lysosomal Nutrient Sensing and Metabolic Signaling
Lysosomal Quality Control and Cellular Adaptation
Lysosome-Associated Diseases and Emerging Therapeutic
Opportunities
